Ii-Key hybrid polypeptide and preparation method and application of tumor vaccine of Ii-Key hybrid polypeptide

A tumor vaccine and tumor technology, applied in the field of anti-tumor drugs, can solve the problems of inability to completely kill tumor cells, poor prognosis, lack of immune response, etc., achieve unique anti-cancer mechanism, improve anti-cancer efficacy, and eliminate MHC restrictions.

Inactive Publication Date: 2020-04-21
深圳市博圣康生物科技有限公司
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Second-line endocrine therapy and chemotherapy (such as docetaxel, cabazitaxel, etc.) can delay tumor progression to a certain extent and prolong patient survival, but they still cannot completely kill tumor cells
25% of BCa found to have high expression of HER2 / neu, which often leads to poor prognosis
[0012] Preliminary results from clinical trials of the vaccine confirm the safety of the vaccine, but also demonstrate the lack of immune response if the vaccine dose is low and / or given infrequently
Moreover, peptide-specific cytotoxic T lymphocyte (CTL) responses were extremely weak 6 months after the end of vaccination

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ii-Key hybrid polypeptide and preparation method and application of tumor vaccine of Ii-Key hybrid polypeptide
  • Ii-Key hybrid polypeptide and preparation method and application of tumor vaccine of Ii-Key hybrid polypeptide
  • Ii-Key hybrid polypeptide and preparation method and application of tumor vaccine of Ii-Key hybrid polypeptide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0056] Below in conjunction with specific embodiment and accompanying drawing, the present invention is further elaborated and illustrated:

[0057] The present invention provides an Ii-Key hybrid polypeptide, wherein the LRMK tetrapeptide in the amino acid sequence of the stable polypeptide chain (Ii) of the MHC class II molecule is connected with a polypeptide capable of being recognized by TH cells through a suitable linker, which can significantly enhance the immune response. Among them, the Ii-Key tetrapeptide can be linked to the following TH polypeptide:

[0058] a), Cytochrome C: PGCC (95-104)

[0059] b), HER2 / neu(777-790)

[0060] c), gp-100 (48-58)

[0061] d), Cytochrome C: PGCC (81-104)

[0062] e), myelin basic protein (MBP 90-102)

[0063] f), HPVgp160 (843-852)

[0064] g), HPV gag (279-272)

[0065] h), HER2 / neu (776-790)

[0066] The preparation method of Ii-Key hybrid polypeptide vaccine comprises the steps:

[0067] Step 1: Resin selection.

[0068...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an Ii-Key hybrid polypeptide. LRMK tetrapeptide in the amino acid sequence of a stable polypeptide chain (Ii) of MHC class II molecules can be linked by polypeptide recognizedby TH cells, shows MHC class II molecule binding efficacy greater than 250 times in vitro, and is easier to recognize and present by antigen presenting cells. The invention provides a preparation method of a hybrid polypeptide tumor vaccine and application of a combination of the hybrid polypeptide tumor vaccine and an immunologic adjuvant, namely granulocyte-macrophage colony stimulating factor (GM-CSF) to treatment of cancers. The hybrid polypeptide tumor vaccine disclosed by the invention is an efficient cancer immunotherapy vaccine for activating an autoimmune system with a latest mechanism. The Ii-Key hybrid polypeptide tumor vaccine provided by the invention has the advantage of improved anti-cancer effect.

Description

technical field [0001] The invention relates to the technical field of antitumor drugs, in particular to an Ii-Key hybrid polypeptide tumor vaccine. Background technique [0002] Prostate cancer (PCa) is a relatively common malignant tumor of the male reproductive system, and its incidence rate ranks second among all male malignant tumors worldwide; in the United States, its incidence rate has surpassed lung cancer and become the first A tumor that seriously threatens men's health. Although the incidence of prostate cancer in my country is lower than that in western countries, in recent years, with the aging of the population, the improvement of people's health awareness, the change of diet structure and the continuous improvement of diagnostic technology, the incidence and mortality of prostate cancer have shown a significant upward trend. It is becoming an important malignant tumor affecting the health of men in our country. Taking Shanghai as an example, the incidence of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00C07K1/36C07K1/30C07K1/20C07K1/08C07K1/06C07K1/04A61K39/00A61P35/00
CPCA61K39/0011A61P35/00A61K39/001106A61K2039/812A61K2039/884A61K2039/892C07K5/101C07K7/06C07K7/08C07K2319/00Y02P20/55
Inventor 杨寅柯高红
Owner 深圳市博圣康生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap